ArticlePloS one2016
Efficacy of the Quorum Sensing Inhibitor FS10 Alone and in Combination with Tigecycline in an Animal Model of Staphylococcal Infected Wound.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 57 citations in OpenAlex.
- Quorum-Sensing Inhibitors as Potential Antibacterial Agents Against Staphylococcus aureus: A Comprehensive Review.Chemistry & biodiversity · 2026Review
- Research Progress on Antivirulence Agents Targeting the Accessory Gene Regulator (Agr) System ofInfection and drug resistance · 2026Review
- An insight on the powerful of bacterial quorum sensing inhibition.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- The role of the skin microbiome in wound healing.Burns & trauma · 2024Review
- Drug delivery strategies for antibiofilm therapy.Nature reviews. Microbiology · 2023Review
- Biofilm and wound healing: from bench to bedside.European journal of medical research · 2023Review
- Drugs for the Quorum Sensing Inhibition of Oral Biofilm: New Frontiers and Insights in the Treatment of Periodontitis.Pharmaceutics · 2022Review
- MRSA and Skin Infections in Psoriatic Patients: Therapeutic Options and New Perspectives.Antibiotics (Basel, Switzerland) · 2022Article
- Preparation, Characterization, and Biological Evaluation of a Hydrophilic Peptide Loaded on PEG-PLGA Nanoparticles.Pharmaceutics · 2022Article
- Synthesis and Biological Evaluation of Novel Cinnamic Acid-Based Antimicrobials.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Nonconformity of biofilm formation in vivo and in vitro based on Staphylococcus aureus accessory gene regulator status.Scientific reports · 2022Article
- Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies.Frontiers in cellular and infection microbiology · 2022Review
- Methicillin-resistant Staphylococcus aureus as a cause of chronic wound infections: Alternative strategies for management.AIMS microbiology · 2022Review
- New Perspectives on Old and New Therapies of Staphylococcal Skin Infections: The Role of Biofilm Targeting in Wound Healing.Antibiotics (Basel, Switzerland) · 2021Review
- Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model.Antibiotics (Basel, Switzerland) · 2021Article
- Acyl homoserine lactone-mediated quorum sensing in the oral cavity: a paradigm revisited.Scientific reports · 2020Article
- New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection.Antimicrobial agents and chemotherapy · 2020Article
- Short-ChainApplied and environmental microbiology · 2020Article
- Recent Advances in Non-Conventional Antimicrobial Approaches for Chronic Wound Biofilms: Have We Found the 'Chink in the Armor'?Biomedicines · 2019Review
- Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?Clinical microbiology reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In staphylococci, quorum sensing regulates both biofilm formation and toxin production, moreover it has been demonstrated to be inhibited by RNAIII inhibiting peptide (RIP). Aim our study was to evaluate the in vitro activity and its in vivo efficacy of the combined administration of FS10, a novel RIP derivative, and tigecycline in an animal model of methicillin-resistant (MR) and methicillin-sensitive (MS) Staphylococcus aureus wound infection. Using a 1.x2 cm template, one full thickness wound was established through the panniculus carnosus on the back subcutaneous tissue of each animal. Infection was determined by inoculation of 5x107 CFU/ml of bacteria, that produced an abscess within 24 h, after this, treatment was initiated. The study included, for each strain, a control group without infection, a control infected group that did not receive any treatment and a control infected group with drug-free foam dressing, and three infected groups treated, respectively, with: FS10-soaked foam dressing (containing 20 μg FS10), daily intraperitoneal tigecycline (7 mg/Kg), FS10-soaked foam dressing (containing 20 μg FS10) and daily intraperitoneal injections of tigecycline (7 mg/Kg). The main outcome measures were quantitative culture and histological examination of tissue repair. The highest inhibition of infection was achieved in the group that received FS10-soaked and parenteral tigecycline reducing the bacterial load from 107 CFU/ml to about 103 CFU/g for MSSA and to about 104 CFU/g for MRSA. The group treated with FS10-soaked foam dressing associated with parenteral tigecycline showed, histologically, better overall healing with epithelialization and collagen scores significantly higher than those of the other groups in both strains. In conclusion, the combined use of topical FS10 with i.p. tigecycline induced positive interaction in vivo, resulting in an enhanced therapeutic benefit versus staphylococcal infections in murine wound models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.